Video

Dr. Petrylak on important updates in bladder cancer from NY GU 2022

Author(s):

Urology Times staff

“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.

In this video, Daniel P. Petrylak, MD, PhD, discusses major takeaways and ongoing research in urothelial cancer, which was presented on at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Petrylak is the director of genitourinary oncology, a professor of medicine and urology, co-leader of Cancer Signaling Networks, and co-director of the Signal Transduction Program at the Yale University Cancer Center in New Haven, Connecticut.

Related Videos
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Related Content
Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC
October 3rd 2024

Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC

Hannah Clarke
In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
September 27th 2024

3D bioprinting technology facilitates development of an in vitro biomimetic bladder model

Kate Gessner, MD, PhD Philip Abbosh, MD, PhD
"This exciting and innovative technology has a wide range of possible applications, including tissue engineering, drug development, and precision medicine," write Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.
female doctor talking with male patient
December 22nd 2022

Dr. Katherine Rotker on destigmatizing sexual health

Urology Times staff
"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.
Enfortumab vedotin plus pembrolizumab approved in Japan for urothelial carcinoma
September 24th 2024

Enfortumab vedotin plus pembrolizumab approved in Japan for urothelial carcinoma

Hannah Clarke
Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW.
Plasma ctDNA clearance may be associated with improved outcomes in MIBC
September 23rd 2024

Plasma ctDNA clearance may be associated with improved outcomes in MIBC

Hannah Clarke
According to the authors, these findings from the VOLGA trial suggest that ctDNA may be a potential biomarker to predict therapeutic benefit in patients with MIBC.
© 2024 MJH Life Sciences

All rights reserved.